

Sarah Fidler

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7983615/sarah-fidler-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

139
papers

4,159
citations

32
h-index

62
g-index

151
ext. papers

5,336
ext. citations

7
avg. IF

4.79
L-index

#	Paper	IF	Citations
139	Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound.. <i>Scientific Reports</i> , 2022 , 12, 462	4.9	1
138	Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.. <i>EclinicalMedicine</i> , 2022 , 44, 101262	11.3	8
137	Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19.. <i>Journal of the International AIDS Society</i> , 2022 , 25, e25882	5.4	2
136	Closing the gap: did delivery approaches complementary to home-based testing reach men with HIV testing services during and after the HPTN 071 (PopART) trial in Zambia?. <i>Journal of the International AIDS Society</i> , 2022 , 25, e25855	5.4	
135	Intimate Partner Violence (IPV) and Associated Factors in HPTN 071 (PopART) Study Communities in Zambia and South Africa-A Comparison by HIV Status.. <i>AIDS and Behavior</i> , 2022 , 26, 1355	4.3	
134	Response to The use of tenofovir in patients with COVID-19 <i>HIV Medicine</i> , 2022 ,	2.7	1
133	The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.. <i>Trials</i> , 2022 , 23, 263	2.8	0
132	HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory T _H cells.. <i>Cell Reports</i> , 2022 , 39, 110650	10.6	1
131	Improving retention of community-recruited participants in HIV prevention research through Saturday household visits; findings from the HPTN 071 (PopART) study in South Africa. <i>BMC Medical Research Methodology</i> , 2021 , 21, 242	4.7	0
130	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. <i>Nature Medicine</i> , 2021 ,	50.5	16
129	Community-based health workers implementing universal access to HIV testing and treatment: lessons from South Africa and Zambia-HPTN 071 (PopART). <i>Health Policy and Planning</i> , 2021 , 36, 881-890 ^{3.4}	3.4	0
128	Tolerability of four-drug antiretroviral combination therapy in primary HIV-1 infection. <i>HIV Medicine</i> , 2021 , 22, 770-774	2.7	1
127	Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8 T _H cell antiviral responses. <i>Cell Reports</i> , 2021 , 35, 109103	10.6	0
126	Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial. <i>The Lancet Global Health</i> , 2021 , 9, e668-e680	13.6	5
125	Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy. <i>Frontiers in Immunology</i> , 2021 , 12, 647688	8.4	1
124	Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort. <i>Aids</i> , 2021 , 35, 2073-2084	3.5	
123	Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis. <i>BMJ Neurology Open</i> , 2021 , 3, e000143	1.5	8

122	Epigenetic scars of CD8 T cell exhaustion persist after cure of chronic infection in humans. <i>Nature Immunology</i> , 2021 , 22, 1020-1029	19.1	24
121	Engaging young people in the design of a sexual reproductive health intervention: Lessons learnt from the Yathu Yathu ("For us, by us") formative study in Zambia. <i>BMC Health Services Research</i> , 2021 , 21, 753	2.9	7
120	HIV Care Cascade Among Adolescents in a "Test and Treat" Community-Based Intervention: HPTN 071 (PopART) for Youth Study. <i>Journal of Adolescent Health</i> , 2021 , 68, 719-727	5.8	3
119	The under-representation of BAME patients in the COVID-19 Recovery trial at a major London NHS Trust. <i>Journal of Infection</i> , 2021 , 82, 84-123	18.9	2
118	HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper. <i>Journal of Virus Eradication</i> , 2021 , 7, 100025	2.8	6
117	Universal HIV testing and treatment and HIV stigma reduction: a comparative thematic analysis of qualitative data from the HPTN 071 (PopART) trial in South Africa and Zambia. <i>Sociology of Health and Illness</i> , 2021 , 43, 167-185	3	5
116	The act of telling: South African women's narratives of HIV status disclosure to intimate partners in the HPTN 071 (PopART) HIV prevention trial. <i>Women's Health</i> , 2021 , 17, 1745506521998204	3	1
115	Outcomes of fertility investigations in a cohort of adults with perinatally acquired HIV-1 infection: a UK cross-sectional observational study. <i>Aids</i> , 2021 , 35, 343-345	3.5	0
114	Acceptability and Preferences of Two Different Community Models of ART Delivery in a High Prevalence Urban Setting in Zambia: Cluster-Randomized Trial, Nested in the HPTN 071 (PopART) Study. <i>AIDS and Behavior</i> , 2021 , 1	4.3	1
113	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV</i> , 2021 , 8, e474-e485	7.8	62
112	PopART-IBM, a highly efficient stochastic individual-based simulation model of generalised HIV epidemics developed in the context of the HPTN 071 (PopART) trial. <i>PLoS Computational Biology</i> , 2021 , 17, e1009301	5	0
111	Clinical outcomes of patients with and without HIV hospitalized with COVID-19 in England during the early stages of the pandemic: a matched retrospective multi-centre analysis (RECEDE-C19 study). <i>HIV Medicine</i> , 2021 ,	2.7	5
110	No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach. <i>Journal of Virus Eradication</i> , 2021 , 7, 100056	2.8	
109	Yathu Yathu ("For us, by us"): Design of a cluster-randomised trial of the impact of community-based, peer-led comprehensive sexual and reproductive health services for adolescents and young people aged 15 to 24 in Lusaka, Zambia. <i>Contemporary Clinical Trials</i> , 2021 , 110, 106568	2.3	2
108	Motivating people living with HIV to initiate antiretroviral treatment outside national guidelines in three clinics in the HPTN 071 (PopART) trial, South Africa. <i>African Journal of AIDS Research</i> , 2021 , 20, 32-41	1.8	
107	Validation of population-level HIV-1 incidence estimation by cross-sectional incidence assays in the HPTN 071 (PopART) trial.. <i>Journal of the International AIDS Society</i> , 2021 , 24, e25830	5.4	2
106	Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study. <i>Journal of NeuroVirology</i> , 2021 , 1	3.9	0
105	Evaluation of multi-assay algorithms for identifying individuals with recent HIV infection: HPTN 071 (PopART).. <i>PLoS ONE</i> , 2021 , 16, e0258644	3.7	0

104	Immunotherapeutic approaches to HIV cure and remission. <i>Current Opinion in Infectious Diseases</i> , 2021 , 35,	5.4	2
103	The effect of universal testing and treatment on HIV stigma in 21 communities in Zambia and South Africa. <i>Aids</i> , 2020 , 34, 2125-2135	3.5	6
102	Mapping of HIV-1C Transmission Networks Reveals Extensive Spread of Viral Lineages Across Villages in Botswana Treatment-as-Prevention Trial. <i>Journal of Infectious Diseases</i> , 2020 , 222, 1670-1680	7	3
101	Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. <i>Lancet, The</i> , 2020 , 395, 888-898	40	41
100	Determination of HIV status and identification of incident HIV infections in a large, community-randomized trial: HPTN 071 (PopART). <i>Journal of the International AIDS Society</i> , 2020 , 23, e25452	5.4	3
99	What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?. <i>Journal of the International AIDS Society</i> , 2020 , 23, e25455	5.4	44
98	Stigma and Judgment Toward People Living with HIV and Key Population Groups Among Three Cadres of Health Workers in South Africa and Zambia: Analysis of Data from the HPTN 071 (PopART) Trial. <i>AIDS Patient Care and STDs</i> , 2020 , 34, 38-50	5.8	13
97	Quantifying HIV transmission flow between high-prevalence hotspots and surrounding communities: a population-based study in Rakai, Uganda. <i>Lancet HIV,the</i> , 2020 , 7, e173-e183	7.8	26
96	HIV testing and treatment coverage achieved after 4 years across 14 urban and peri-urban communities in Zambia and South Africa: An analysis of findings from the HPTN 071 (PopART) trial. <i>PLoS Medicine</i> , 2020 , 17, e1003067	11.6	6
95	HIV Stigma and Viral Suppression Among People Living With HIV in the Context of Universal Test and Treat: Analysis of Data From the HPTN 071 (PopART) Trial in Zambia and South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 85, 561-570	3.1	6
94	Psychotic disorders in young adults with perinatally acquired HIV: a UK case series. <i>Psychological Medicine</i> , 2020 , 1-7	6.9	1
93	Compromised CD4:CD8 ratio recovery in people living with HIV aged over 50 years: an observational study. <i>HIV Medicine</i> , 2020 , 21, 109-118	2.7	4
92	Clinical outcomes post transition to adult services in young adults with perinatally acquired HIV infection: mortality, retention in care and viral suppression. <i>Aids</i> , 2020 , 34, 261-266	3.5	11
91	Levels of Human Immunodeficiency Virus DNA Are Determined Before ART Initiation and Linked to CD8 T-Cell Activation and Memory Expansion. <i>Journal of Infectious Diseases</i> , 2020 , 221, 1135-1145	7	7
90	A randomised feasibility trial of an intervention to support sharing of HIV status for 18-25-year olds living with perinatally acquired HIV compared with standard care: HIV Empowering AdultsN Decisions to Share-UK/Uganda Project (HEADS-UP). <i>Pilot and Feasibility Studies</i> , 2020 , 6, 141	1.9	
89	A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in Low-Income Settings. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.7	15
88	A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection. <i>EBioMedicine</i> , 2020 , 59, 102853	8.8	5
87	Association between HIV stigma and antiretroviral therapy adherence among adults living with HIV: baseline findings from the HPTN 071 (PopART) trial in Zambia and South Africa. <i>Tropical Medicine and International Health</i> , 2020 , 25, 1246-1260	2.3	6

86	Better Virological Outcomes Among People Living With Human Immunodeficiency Virus (HIV) Initiating Early Antiretroviral Treatment (CD4 Counts ≥ 500 Cells/ μ L) in the HIV Prevention Trials Network 071 (PopART) Trial in South Africa. <i>Clinical Infectious Diseases</i> , 2020 , 70, 395-403	11.6	9
85	CD32 expressing doublets in HIV-infected gut-associated lymphoid tissue are associated with a T follicular helper cell phenotype. <i>Mucosal Immunology</i> , 2019 , 12, 1212-1219	9.2	16
84	Renal dysfunction by baseline CD4 cell count in a cohort of adults starting antiretroviral treatment regardless of CD4 count in the HIV Prevention Trials Network 071 [HPTN 071; Population Effect of Antiretroviral Therapy to Reduce HIV Transmission (PopART)] study in South Africa. <i>HIV Medicine</i> , 2019 , 20, 392-403	2.7	1
83	Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART). <i>New England Journal of Medicine</i> , 2019 , 381, 207-218	59.2	149
82	Mapping the drivers of within-host pathogen evolution using massive data sets. <i>Nature Communications</i> , 2019 , 10, 3017	17.4	4
81	Responses to Quadrivalent Influenza Vaccine Reveal Distinct Circulating CD4+CXCR5+ T Cell Subsets in Men Living with HIV. <i>Scientific Reports</i> , 2019 , 9, 15650	4.9	2
80	Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review. <i>Journal of the International AIDS Society</i> , 2019 , 22, e25419	5.4	24
79	Soluble plasma programmed death 1 (PD-1) and Tim-3 in primary HIV infection. <i>Aids</i> , 2019 , 33, 1253-1256	5.5	10
78	Community based distribution of oral HIV self-testing kits in Zambia: a cluster-randomised trial nested in four HPTN 071 (PopART) intervention communities. <i>Lancet HIV</i> , 2019 , 6, e81-e92	7.8	58
77	Virological remission after antiretroviral therapy interruption in female African HIV seroconverters. <i>Aids</i> , 2019 , 33, 185-197	3.5	7
76	Reasons for delayed antiretroviral therapy (ART) initiation in the era of early ART initiation guidelines: a retrospective service evaluation. <i>International Journal of STD and AIDS</i> , 2019 , 30, 415-418	1.4	7
75	Understanding the Time Needed to Link to Care and Start ART in Seven HPTN 071 (PopART) Study Communities in Zambia and South Africa. <i>AIDS and Behavior</i> , 2019 , 23, 929-946	4.3	33
74	A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system. <i>Npj Vaccines</i> , 2018 , 3, 2	9.5	13
73	Incidence of Tuberculosis Among HIV-Positive Individuals Initiating Antiretroviral Treatment at Higher CD4 Counts in the HPTN 071 (PopART) Trial in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 77, 93-101	3.1	15
72	CD4:CD8 ratio in children with perinatally acquired HIV-1 infection. <i>HIV Medicine</i> , 2018 , 19, 668-672	2.7	3
71	A study on the dynamics of temporary HIV treatment to assess the controversial outcomes of clinical trials: An in-silico approach. <i>PLoS ONE</i> , 2018 , 13, e0200892	3.7	5
70	CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA. <i>Frontiers in Immunology</i> , 2018 , 9, 928	8.4	26
69	Hospital-based routine HIV testing in high-income countries: a systematic literature review. <i>HIV Medicine</i> , 2018 , 19, 195-205	2.7	11

68	Attrition when providing antiretroviral treatment at CD4 counts >500cells/ μ l at three government clinics included in the HPTN 071 (PopART) trial in South Africa. <i>PLoS ONE</i> , 2018 , 13, e0195127	3.7	11
67	Spinning plates: livelihood mobility, household responsibility and anti-retroviral treatment in an urban Zambian community during the HPTN 071 (PopART) study. <i>Journal of the International AIDS Society</i> , 2018 , 21 Suppl 4, e25117	5.4	9
66	Towards 90-90: Findings after two years of the HPTN 071 (PopART) cluster-randomized trial of a universal testing-and-treatment intervention in Zambia. <i>PLoS ONE</i> , 2018 , 13, e0197904	3.7	33
65	Retrospective review of routine clinical patient experiences with dolutegravir; virological suppression, immunological recovery and adverse events. <i>HIV Medicine</i> , 2017 , 18, 709-710	2.7	5
64	What works - reaching universal HIV testing: lessons from HPTN 071 (PopART) trial in Zambia. <i>Aids</i> , 2017 , 31, 1555-1564	3.5	26
63	Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial. <i>The Lancet Global Health</i> , 2017 , 5, e1133-e1141	13.6	20
62	A qualitative study exploring the social and environmental context of recently acquired HIV infection among men who have sex with men in South-East England. <i>BMJ Open</i> , 2017 , 7, e016494	3	10
61	Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. <i>Journal of the International AIDS Society</i> , 2017 , 20, 21579	5.4	72
60	A pilot evaluation of whole blood finger-prick sampling for point-of-care HIV viral load measurement: the UNICORN study. <i>Scientific Reports</i> , 2017 , 7, 13658	4.9	11
59	Understanding low sensitivity of community-based HIV rapid testing: experiences from the HPTN 071 (PopART) trial in Zambia and South Africa. <i>Journal of the International AIDS Society</i> , 2017 , 20, 21780	5.4	16
58	Community intervention improves knowledge of HIV status of adolescents in Zambia: findings from HPTN 071-PopART for youth study. <i>Aids</i> , 2017 , 31 Suppl 3, S221-S232	3.5	30
57	Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 74, 126-133	3.1	21
56	Predictors of timely linkage-to-ART within universal test and treat in the HPTN 071 (PopART) trial in Zambia and South Africa: findings from a nested case-control study. <i>Journal of the International AIDS Society</i> , 2017 , 20, e25037	5.4	32
55	A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial. <i>PLoS Medicine</i> , 2017 , 14, e1002292	11.6	81
54	HIV-related stigma and universal testing and treatment for HIV prevention and care: design of an implementation science evaluation nested in the HPTN 071 (PopART) cluster-randomized trial in Zambia and South Africa. <i>Health Policy and Planning</i> , 2016 , 31, 1342-1354	3.4	33
53	"The difference that makes a difference": highlighting the role of variable contexts within an HIV Prevention Community Randomised Trial (HPTN 071/PopART) in 21 study communities in Zambia and South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016 , 28 Suppl 3, 99-107	2.2	18
52	Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation. <i>HIV Medicine</i> , 2016 , 17, 368-72	2.7	5
51	Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function. <i>PLoS Pathogens</i> , 2016 , 12, e1005782	7.6	32

50	Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection. <i>PLoS Pathogens</i> , 2016 , 12, e1005661	7.6	98
49	International AIDS Society global scientific strategy: towards an HIV cure 2016. <i>Nature Medicine</i> , 2016 , 22, 839-50	50.5	303
48	Primary HIV infection: a medical and public health emergency requiring rapid specialist management. <i>Clinical Medicine</i> , 2016 , 16, 180-3	1.9	2
47	Using nearly full-genome HIV sequence data improves phylogeny reconstruction in a simulated epidemic. <i>Scientific Reports</i> , 2016 , 6, 39489	4.9	20
46	Structured observations reveal slow HIV-1 CTL escape. <i>PLoS Genetics</i> , 2015 , 11, e1004914	6	24
45	HIV treatment-as-prevention research: taking the right road at the crossroads. <i>PLoS Medicine</i> , 2015 , 12, e1001800	11.6	6
44	Advancing the HIV cure agenda: the next 5 years. <i>Current Opinion in Infectious Diseases</i> , 2015 , 28, 1-9	5.4	16
43	Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. <i>Nature Communications</i> , 2015 , 6, 8495	17.4	108
42	Post-treatment control: a functional cure for HIV. <i>Future Virology</i> , 2015 , 10, 1245-1256	2.4	
41	P14.13 Hiv-related stigma and universal testing and treatment for hiv prevention and care: design of an implementation science evaluation nested in the hptn 071 (popart) cluster-randomised trial in zambia and south africa. <i>Sexually Transmitted Infections</i> , 2015 , 91, A202.3-A203	2.8	
40	Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controls. <i>HIV Clinical Trials</i> , 2015 , 16, 81-7		4
39	IAS Towards an HIV Cure Symposium: people focused, science driven: 18-19 July 2015, Vancouver, Canada. <i>Journal of Virus Eradication</i> , 2015 , 1, 276-81	2.8	0
38	HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial. <i>Trials</i> , 2014 , 15, 57	2.8	155
37	Facing the Realities of HIV Universal Test and Treat: Early Lessons Learned from the Delivery of the HPTN071/ PopART Study Intervention in Zambia. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A72-A73		16
36	Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression. <i>Aids</i> , 2014 , 28, 869-74	3.5	23
35	The importance of viral blips and duration of therapy initiated in primary infection in maintaining viral control after stopping cART. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19820	5.4	3
34	Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19480	5.4	35
33	How Many HIV infections may be averted by targeting primary infection in men who have sex with men? Quantification of changes in transmission-risk behavior, using an individual-based model. <i>Journal of Infectious Diseases</i> , 2014 , 210 Suppl 2, S594-9	7	10

32	HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. <i>PLoS ONE</i> , 2014 , 9, e84511	3.7	80
31	HIV-1 DNA predicts disease progression and post-treatment virological control. <i>ELife</i> , 2014 , 3, e03821	8.9	210
30	The detection and management of early HIV infection: a clinical and public health emergency. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 63 Suppl 2, S187-99	3.1	43
29	Short-course antiretroviral therapy in primary HIV infection. <i>New England Journal of Medicine</i> , 2013 , 368, 207-17	59.2	164
28	Prophylactic antiretroviral HIV therapy prevents infection in heterosexual men and women. <i>Evidence-Based Medicine</i> , 2013 , 18, 184-5		3
27	Position statement on the use of antiretroviral therapy to reduce HIV transmission, January 2013: the British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA). <i>HIV Medicine</i> , 2013 , 14, 259-62	2.7	14
26	P6.021 Characteristics of High Risk MSM into a Repeat Self-Sampling HIV-1 Antibody Testing Feasibility and Acceptability Pilot. <i>Sexually Transmitted Infections</i> , 2013 , 89, A376.1-A376	2.8	
25	Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. <i>PLoS ONE</i> , 2013 , 8, e78287	3.7	60
24	Comparison of sexual behavior and HIV risk between two HIV-1 serodiscordant couple cohorts: the CHAVI 002 study. <i>PLoS ONE</i> , 2012 , 7, e37727	3.7	4
23	Missed opportunities for identifying primary HIV within genitourinary medical/HIV services. <i>International Journal of STD and AIDS</i> , 2012 , 23, 540-3	1.4	2
22	Clinical evaluation of the Determine HIV-1/2 Ag/Ab Combo test. <i>Journal of Infectious Diseases</i> , 2012 , 206, 1947-9; author reply 1949-50	7	14
21	Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. <i>Journal of Infectious Diseases</i> , 2012 , 206, 552-61	7	67
20	O1-S11.03 How many infections are averted by behaviour change after early HIV diagnosis & counselling of MSM? Estimates from a stochastic individual-based model. <i>Sexually Transmitted Infections</i> , 2011 , 87, A51-A52	2.8	
19	Universal testing and treatment as an HIV prevention strategy: research questions and methods. <i>Current HIV Research</i> , 2011 , 9, 429-45	1.3	54
18	Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals. <i>Journal of Virology</i> , 2011 , 85, 3507-16	6.6	32
17	The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. <i>Science</i> , 2010 , 330, 1551-7	33.3	884
16	High rates of asymptomatic neurocognitive impairment in vertically acquired HIV-1-infected adolescents surviving to adulthood. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 55, 134-6	3.1	35
15	Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission. <i>Aids</i> , 2010 , 24 Suppl 4, S27-39	3.5	28

14	Antiretroviral treatment of primary HIV infection to reduce onward transmission. <i>Current Opinion in HIV and AIDS</i> , 2010 , 5, 283-90	4.2	26
13	Sexual transmission of HIV-1. <i>Antiviral Research</i> , 2010 , 85, 276-85	10.8	60
12	HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection. <i>Journal of Virology</i> , 2009 , 83, 1228-39	6.6	39
11	Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. <i>HIV Medicine</i> , 2009 , 10, 432-8	2.7	120
10	Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection. <i>Clinical and Experimental Immunology</i> , 2008 , 152, 532-7	6.2	2
9	Primary HIV infection: to treat or not to treat?. <i>Current Opinion in Infectious Diseases</i> , 2008 , 21, 4-10	5.4	22
8	Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. <i>Aids</i> , 2007 , 21, 1283-91	3.5	25
7	Passive sexual transmission of human immunodeficiency virus type 1 variants and adaptation in new hosts. <i>Journal of Virology</i> , 2006 , 80, 7226-34	6.6	22
6	Comparative potency of three antiretroviral therapy regimes in primary HIV infection. <i>Aids</i> , 2006 , 20, 247-52	3.5	11
5	Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. <i>HIV Medicine</i> , 2004 , 5, 180-4	2.7	51
4	Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. <i>Aids</i> , 2002 , 16, 2049-54	3.5	42
3	HIV-1 drug resistance in primary infections in the UK 2001 , 323, 632-632		7
2	T-cell activation: a cellular target for antiretroviral therapy. <i>European Journal of Clinical Investigation</i> , 2000 , 30, 95-8	4.6	2
1	Mapping the drivers of within-host pathogen evolution using massive data sets		1